NQ Oncology

NQ Oncology is a clinical-stage biotechnology company focused on the development of novel cancer therapies targeting NQO1-overexpressing malignancies. The company's lead program, ARQ 761, is a clinical-stage small molecule formulation of beta-lapachone that selectively targets the NQO1 enzyme to induce tumor-specific cell death. NQ Oncology has collaborated with ArQule (now part of Merck) to advance ARQ 761 through Phase 1 clinical trials for various solid tumors, including pancreatic and lung cancers. The company was co-founded by seasoned healthcare executives William Hoos and Michael Hufford and leverages quantitative proteomics to identify patients most likely to respond to its NQO1-targeted therapies.